Home Biosimilar Antibodies Immunology & Inflammation Antioxidant Ozuriftamab (Anti-ROR2)
For research use only. Not for use in humans.

Ozuriftamab (Anti-ROR2)

Synonyms: BA3021

Ozuriftamab (Anti-ROR2) is a naked human IgG1 kappa antibody targeting receptor tyrosine kinase-like orphan receptor 2 ROR.It has antineoplastic activity and can be used in research of head and neck squamous cell cancer (HNSCC)

Ozuriftamab (Anti-ROR2)

2 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A316201 Purity: 99% Protein concentration: 4.31mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Ozuriftamab (Anti-ROR2) is a naked human IgG1 kappa antibody targeting receptor tyrosine kinase-like orphan receptor 2 ROR.It has antineoplastic activity and can be used in research of head and neck squamous cell cancer (HNSCC)
References

Product Details

CAS No. 2460399-44-2
Isotype Human IgG1
Source CHO
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05271604 COMPLETED Head and Neck Cancer; Squamous Cell Carcinoma of Head and Neck; Recurrent Squamous Cell Carcinoma of the Head and Neck; Metastatic Cancer; Metastatic Squamous Cell Carcinoma of the Head and Neck BioAtla, Inc. 2022-12-13 PHASE2

(data from https://clinicaltrials.gov, updated on 2025-09-26)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.